Home
NTLA
NTLA News

Latest Intellia Therapeutics Inc. (NTLA) News on July 27, 2024

Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

Zacks

11 hours ago

Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 days ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Simply Wall St.

10 days ago

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

Zacks

10 days ago

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy

Zacks

15 days ago

All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy

The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger

Motley Fool

18 days ago

The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger

3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024

Motley Fool

25 days ago

3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024

Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down

Zacks

a month ago

Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down

MT Newswires

a month ago

Intellia Therapeutics Names Edward Dulac CFO

Intellia Therapeutics Announces CFO Transition

GlobeNewswire

a month ago

Intellia Therapeutics Announces CFO Transition

First-of-its-kind Intellia data suggest CRISPR drug could be given more than once

BioPharma Dive

a month ago

First-of-its-kind Intellia data suggest CRISPR drug could be given more than once

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

GlobeNewswire

a month ago

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

GlobeNewswire

a month ago

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry

Zacks

a month ago

Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry

Intellia Therapeutics Names Brian Goff to its Board of Directors

GlobeNewswire

a month ago

Intellia Therapeutics Names Brian Goff to its Board of Directors

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

2 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

2 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

2 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

2 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

2 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

2 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

PR Newswire

2 months ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

2 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought

Motley Fool

2 months ago

Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought

These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now

Motley Fool

2 months ago

These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Motley Fool

2 months ago

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Reuters

2 months ago

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Simply Wall St.

2 months ago

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)

GuruFocus.com

2 months ago

Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)

Insider Sale: CFO Steven Tomsic Sells 30,000 Shares of Fox Corp (FOX)

GuruFocus.com

2 months ago

Insider Sale: CFO Steven Tomsic Sells 30,000 Shares of Fox Corp (FOX)

Insider Sale: Chief Legal Officer Jeff Lendino Sells Shares of Jamf Holding Corp (JAMF)

GuruFocus.com

2 months ago

Insider Sale: Chief Legal Officer Jeff Lendino Sells Shares of Jamf Holding Corp (JAMF)

Insider Sale: President and CEO Kevin Mcnamara Sells Shares of Chemed Corp (CHE)

GuruFocus.com

2 months ago

Insider Sale: President and CEO Kevin Mcnamara Sells Shares of Chemed Corp (CHE)

Insider Sale: SVP & Chief Accounting Officer Dara Bazzano Sells 4,300 Shares of T-Mobile US ...

GuruFocus.com

2 months ago

Insider Sale: SVP & Chief Accounting Officer Dara Bazzano Sells 4,300 Shares of T-Mobile US ...

Cathie Wood Invests In 2 Biotechnology Stocks – Are They Worth Buying?

Benzinga

2 months ago

Cathie Wood Invests In 2 Biotechnology Stocks – Are They Worth Buying?

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

2 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

It Looks Like Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO May Expect Their Salary To Be Put Under The Microscope

Simply Wall St.

2 months ago

It Looks Like Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO May Expect Their Salary To Be Put Under The Microscope

Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data

Zacks

2 months ago

Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data

Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?

Motley Fool

2 months ago

Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?

Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?

Insider Monkey

2 months ago

Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?

MT Newswires

2 months ago

Update: Intellia Therapeutics Shares Rise as NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate

MT Newswires

2 months ago

Intellia Therapeutics' NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

GlobeNewswire

2 months ago

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

ARK Invest's Cathie Wood Snags These 3 Bargains — Are They Right for Your Portfolio?

Benzinga

2 months ago

ARK Invest's Cathie Wood Snags These 3 Bargains — Are They Right for Your Portfolio?

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

2 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Morningstar Research

2 months ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average

Zacks

2 months ago

Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average

Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Simply Wall St.

2 months ago

Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript

Insider Monkey

3 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript

GuruFocus.com

3 months ago

Intellia Therapeutics Q1 2024 Earnings: Aligns with Analyst Projections Amidst Strategic Advances

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

3 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates

Zacks

3 months ago

Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates

Intellia Therapeutics First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Intellia Therapeutics First Quarter 2024 Earnings: Beats Expectations

Thomson Reuters StreetEvents

3 months ago

Q1 2024 Intellia Therapeutics Inc Earnings Call

Morningstar Research

3 months ago

Analyst Report: Intellia Therapeutics, Inc.

MT Newswires

3 months ago

Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Zacks

3 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire

3 months ago

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today

Zacks

3 months ago

Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

3 months ago

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

GlobeNewswire

3 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

GlobeNewswire

3 months ago

Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?

Zacks

3 months ago

Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Zacks

3 months ago

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

2 Stocks Down 30% to Buy Right Now

Motley Fool

3 months ago

2 Stocks Down 30% to Buy Right Now

Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.

Motley Fool

3 months ago

Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.

Bull Market and Beyond: 3 Stocks Just Waiting to Soar

Motley Fool

4 months ago

Bull Market and Beyond: 3 Stocks Just Waiting to Soar

Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65%

Simply Wall St.

4 months ago

Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65%

Better Cathie Wood Stock: Moderna vs. Intellia

Motley Fool

4 months ago

Better Cathie Wood Stock: Moderna vs. Intellia

Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study

Zacks

4 months ago

Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

GlobeNewswire

4 months ago

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Is Intellia Therapeutics Stock a Buy Now?

Motley Fool

5 months ago

Is Intellia Therapeutics Stock a Buy Now?

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst

Motley Fool

5 months ago

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst

Morningstar Research

5 months ago

Analyst Report: Intellia Therapeutics, Inc.

A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now

Motley Fool

5 months ago

A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now

Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors

Zacks

5 months ago

Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

5 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average

Zacks

5 months ago

Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.

5 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Intellia Therapeutics Full Year 2023 Earnings: Revenues Disappoint

Simply Wall St.

5 months ago

Intellia Therapeutics Full Year 2023 Earnings: Revenues Disappoint

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript

Insider Monkey

5 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript

Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

Zacks

5 months ago

Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?

Zacks

5 months ago

Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?

Thomson Reuters StreetEvents

5 months ago

Q4 2023 Intellia Therapeutics Inc Earnings Call

GuruFocus.com

5 months ago

Intellia Therapeutics Inc (NTLA) Reports Full-Year 2023 Financial Results and Operational Progress

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire

5 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

Zacks

5 months ago

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought

Motley Fool

5 months ago

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought

Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?

Motley Fool

5 months ago

Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks

5 months ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Business Wire

5 months ago

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

Intellia, ReCode partner on genetic medicines for cystic fibrosis

BioPharma Dive

5 months ago

Intellia, ReCode partner on genetic medicines for cystic fibrosis

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

Zacks

5 months ago

5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

GlobeNewswire

5 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

3 Gene Editing Stocks With Unprecedented Surge Potential

InvestorPlace

5 months ago

3 Gene Editing Stocks With Unprecedented Surge Potential

Top 11 CRISPR Stocks To Invest In

Insider Monkey

6 months ago

Top 11 CRISPR Stocks To Invest In

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

InvestorPlace

6 months ago

The 3 Most Undervalued Biotech Stocks to Buy in February 2024

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

6 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Invest In Growth?

Simply Wall St.

6 months ago

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Invest In Growth?

A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist

Motley Fool

6 months ago

A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

GlobeNewswire

6 months ago

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

Share on Social Networks: